Biotechnology · Waltham, Massachusetts, United States
$6.61
-5.57% (-$0.39)2026-08-24
Smart-Money SignalNeutral · 43/100— Insiders are net sellers over 90 days (-$31K, 5 sales vs 1 buy)
Revenue$773.0K
Net Income-$39.7M
EPS$-1.47
Market Cap$362.0M
Price Performance
Historical data including institutional events
Company Profile
E
E. Sutherland
CEO & Executive Director
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
